Combination therapy with decitabine and olaparib in poly(ADP-ribose) polymerase inhibitor (PARPi) resistant high grade serous ovarian cancer

A. Shafa, X. Hou, L. Wang, S. J. Weroha

Research output: Contribution to journalArticlepeer-review

Original languageEnglish (US)
Pages (from-to)S54
JournalEuropean Journal of Cancer
StatePublished - Oct 2022

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this